NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04303741 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT02878057 2021-01-27
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT03394287 2020-10-23
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT02768415 2019-06-19
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03735082 2018-11-08
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03457467 2018-03-07
Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
West China Hospital
Phase 2 Unknown
NCT01176669 2015-09-09
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Fudan University
Phase 2 Completed
NCT01653561 2013-12-03
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Fudan University
Phase 2 Completed